Use your browser's back button to choose another title or click here for a New Search.

How to Get the Poster

 Open poster (ppt)


Bookmark and Share

Feasibility of Conducting Genetics Research at Community Treatment Programs.

Poster presented at the NIDA Blending Conference, "Blending Addiction Science and Practice: Evidence-Based Treatment and Prevention in Diverse Populations and Settings," Albuquerque, NM, April 22-23, 2010.

Susan C. Sonne, Pharm D (Medical University of South Carolina, SC Node), Stephanie Gentilin, MA (Medical University of South Carolina, SC Node), Royce Sampson, MSN, APRN-BC (Medical University of South Carolina, SC Node), Lindsay DeVane, PharmD (Medical University of South Carolina, SC Node), Christie Thomas, MPH (University of California, Los Angeles, CA/AZ Node), Wade Berrettini, MD (University of Pennsylvania, OV Node).

The addition of genetics research to pharmacotherapy trials is becoming more and more common. However, there has been some concern among community treatment providers that genetics research would be unacceptable to their clients. The CTN is currently conducting an add-on genetics substudy to a pharmacotherapy trial comparing the effects of long-term methadone and buprenorphine on liver function (CTN-0027, "Starting Treatment with Agonist Replacement Therapies (START)). The genetics substudy (CTN-0027-A-1) is exploratory in nature, with three main goals: 1) To better understand the potential genetic influence on opioid addiction; 2) To better understand how opioid dependent individuals metabolize buprenorphine and methadone; and 3) To evaluate feasibility of conducting a genetics sub-study within the CTN. Although data are still being collected to accomplish the first two goals, there is good evidence to support the feasibility of collecting genetic samples for analysis through the CTN. To date, all 8 of the START research sites have submitted samples for this substudy. The genetics substudy has 4 different levels of consent so that participants can choose how their samples may be used in the future. Most participants (79%) have agreed to the most liberal use of their samples. Taken together, these data suggest that individuals in community treatment settings are willing to participate in genetic studies on addiction. (Poster, PowerPoint slides, English, 2010)

Keywords: Buprenorphine/Naloxone | Genetics | Pharmacological therapy | Suboxone | NIDA Blending Conference, 2010

Document No: 465

Submitted by Susan Sonne, PharmD, SC Node, 5/20/2010.

Berrettini, Wade search
DeVane, Lindsay search
Gentilin, Stephanie search mail
Sampson, Royce search mail
Thomas, Christie search mail
Sonne, Susan C. search mail

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 5/2010 --